An Improved Method for Culturing Patient-derived Colorectal Cancer Spheroids

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 May 19

PMID 29774115

Citations 25

Authors

Hiroyuki Miyoshi

Hisatsugu Maekawa

Fumihiko Kakizaki

Tadayoshi Yamaura

Kenji Kawada

Yoshiharu Sakai

M Mark Taketo

Affiliations

Soon will be listed here.

Abstract

Recent advances allowed culturing and examination of patient-derived colorectal cancer (PD-CRC) cells as organoids or spheroids. To be applied to practical personalized medicine, however, current methods still need to be strengthened for higher efficiency. Here we report an improved method to propagate PD-CRC tumor initiating cells (TICs) in spheroid culture. We established > 100 cancer spheroid lines derived from independent colorectal cancer patients employing a serum-containing medium with additional inhibitors, Y27632 and SB431542. Because colorectal cancer spheroids showed wide-range growth rates depending on the patient tumors, we searched for supplementary factors that accelerated proliferation of slow-growing CRC-TIC spheroids. To this end, we introduced a convenient growth-monitoring method using a luciferase reporter. We found that epidermal growth factor (EGF) and/or basic fibroblast growth factor (bFGF) were critical for steady propagation of a subset of CRC-TIC spheroids carrying the wild-type and genes. We also identified 5'-(-ethyl-carboxamido)-adenosine (NECA), an adenosine receptor agonist, as an essential supplement for another subset of spheroids. Based on these results, we propose to optimize culture conditions for CRC-TIC spheroids by adjusting to the respective tumor samples. Our method provides a versatile tool that can be applied to personalized chemotherapy evaluation in prospective clinical studies.

Citing Articles

Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch.

Aisu Y, Oshima N, Hyodo F, Elhelaly A, Masuo A, Okada T PLoS One. 2024; 19(12):e0309700.

PMID: 39666615 PMC: 11637386. DOI: 10.1371/journal.pone.0309700.

Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer.

Costa B, Estrada M, Gomes A, Fernandez L, Azevedo J, Povoa V Nat Commun. 2024; 15(1):4771.

PMID: 38839755 PMC: 11153622. DOI: 10.1038/s41467-024-49051-0.

Spheroids and organoids derived from colorectal cancer as tools for drug screening.

Ahmad Zawawi S, Salleh E, Musa M Explor Target Antitumor Ther. 2024; 5(2):409-431.

PMID: 38745769 PMC: 11090692. DOI: 10.37349/etat.2024.00226.

Toward reproducible tumor organoid culture: focusing on primary liver cancer.

Guo L, Li C, Gong W Front Immunol. 2024; 15:1290504.

PMID: 38571961 PMC: 10987700. DOI: 10.3389/fimmu.2024.1290504.

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.

References

Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K . A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell. 2016; 18(6):827-838. DOI: 10.1016/j.stem.2016.04.003. View

Miyoshi H, Ajima R, Luo C, Yamaguchi T, Stappenbeck T . Wnt5a potentiates TGF-β signaling to promote colonic crypt regeneration after tissue injury. Science. 2012; 338(6103):108-13. PMC: 3706630. DOI: 10.1126/science.1223821. View

de Miranda N, van Dinther M, van den Akker B, van Wezel T, Ten Dijke P, Morreau H . Transforming Growth Factor β Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2. Gastroenterology. 2015; 148(7):1427-37.e8. DOI: 10.1053/j.gastro.2015.02.052. View

Carethers J, Jung B . Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology. 2015; 149(5):1177-1190.e3. PMC: 4589489. DOI: 10.1053/j.gastro.2015.06.047. View

Jho E, Zhang T, Domon C, Joo C, Freund J, Costantini F . Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002; 22(4):1172-83. PMC: 134648. DOI: 10.1128/MCB.22.4.1172-1183.2002. View

van de Wetering M, Francies H, Francis J, Bounova G, Iorio F, Pronk A . Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4):933-45. PMC: 6428276. DOI: 10.1016/j.cell.2015.03.053. View

Niwa H, Yamamura K, Miyazaki J . Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193-9. DOI: 10.1016/0378-1119(91)90434-d. View

Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, De Velasco M . Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. Mol Carcinog. 2016; 56(1):106-117. DOI: 10.1002/mc.22476. View

Wei Q, Costanzi S, Balasubramanian R, Gao Z, Jacobson K . A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal. 2013; 9(2):271-80. PMC: 3646116. DOI: 10.1007/s11302-012-9350-3. View

10.

Pauli C, Hopkins B, Prandi D, Shaw R, Fedrizzi T, Sboner A . Personalized and Cancer Models to Guide Precision Medicine. Cancer Discov. 2017; 7(5):462-477. PMC: 5413423. DOI: 10.1158/2159-8290.CD-16-1154. View

11.

Compton C, Fielding L, Burgart L, Conley B, Cooper H, Hamilton S . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):979-94. DOI: 10.5858/2000-124-0979-PFICC. View

12.

Kohne C . Successes and limitations of targeted cancer therapy in colon cancer. Prog Tumor Res. 2014; 41:36-50. DOI: 10.1159/000356436. View

13.

Strohmeier G, Reppert S, Lencer W, Madara J . The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem. 1995; 270(5):2387-94. DOI: 10.1074/jbc.270.5.2387. View

14.

Palorini R, De Rasmo D, Gaviraghi M, Sala Danna L, Signorile A, Cirulli C . Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration. Oncogene. 2012; 32(3):352-62. DOI: 10.1038/onc.2012.50. View

15.

Hidalgo M, Amant F, Biankin A, Budinska E, Byrne A, Caldas C . Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4(9):998-1013. PMC: 4167608. DOI: 10.1158/2159-8290.CD-14-0001. View

16.

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View

17.

Wood L, Parsons D, Jones S, Lin J, Sjoblom T, Leary R . The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-13. DOI: 10.1126/science.1145720. View

18.

Ma D, Kondo T, Nakazawa T, Niu D, Mochizuki K, Kawasaki T . Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol. 2010; 41(11):1550-7. DOI: 10.1016/j.humpath.2010.04.008. View

19.

Morton C, Houghton P . Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007; 2(2):247-50. DOI: 10.1038/nprot.2007.25. View

20.

Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T . A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007; 25(6):681-6. DOI: 10.1038/nbt1310. View